Literature DB >> 11588060

Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms.

P Samorapoompichit1, H P Kiener, G H Schernthaner, J H Jordan, H Agis, F Wimazal, M Baghestanian, A Rezaie-Majd, W R Sperr, K Lechner, P Valent.   

Abstract

Tryptases are serine proteases primarily expressed in mast cells. Normal blood basophils express only trace amounts of the enzyme. However, recent immunohistochemical studies have raised the possibility that neoplastic basophils express significant amounts of tryptase. In this study, tryptase expression was analyzed in normal and neoplastic basophils by immunoelectron microscopy using antitryptase monoclonal antibody G3. Basophils were obtained from patients with chronic myeloid leukemia (CML), idiopathic myelofibrosis (IMF), and myelodysplastic syndrome (MDS), and from healthy donors. Tryptase-immunoreactive material was detected in cytoplasmic granules of basophils in CML, IMF, and MDS. By contrast, normal basophils did not contain significant amounts of tryptase by immunoelectron microscopy. As assessed by reverse transcription-polymerase chain reaction, neoplastic basophils contained messenger RNA (mRNA) for alpha-tryptase, but no beta-tryptase mRNA. In summary, these data provide evidence that neoplastic basophils in CML, IMF, and MDS can express detectable amounts of tryptase. Therefore, tryptase should not be regarded as specific for mast cells when neoplastic myeloid cells are analyzed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588060     DOI: 10.1182/blood.v98.8.2580

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  The distribution of mast cells in the human area postrema.

Authors:  Andrea Porzionato; Veronica Macchi; Anna Parenti; Raffaele De Caro
Journal:  J Anat       Date:  2004-02       Impact factor: 2.610

2.  Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.

Authors:  Peter Valent; Cem Akin; Michel Arock; Knut Brockow; Joseph H Butterfield; Melody C Carter; Mariana Castells; Luis Escribano; Karin Hartmann; Philip Lieberman; Boguslaw Nedoszytko; Alberto Orfao; Lawrence B Schwartz; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Rudolf Valenta; Hans-Peter Horny; Dean D Metcalfe
Journal:  Int Arch Allergy Immunol       Date:  2011-10-27       Impact factor: 2.749

3.  Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.

Authors:  Wolfgang R Sperr; Thomas Pfeiffer; Gregor Hoermann; Susanne Herndlhofer; Christian Sillaber; Christine Mannhalter; Michael Kundi; Peter Valent
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 4.  Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?

Authors:  Theoharis C Theoharides; Irene Tsilioni; Huali Ren
Journal:  Expert Rev Clin Immunol       Date:  2019-04-22       Impact factor: 4.473

Review 5.  Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome.

Authors:  Peter Valent; Cem Akin; Patrizia Bonadonna; Karin Hartmann; Knut Brockow; Marek Niedoszytko; Boguslaw Nedoszytko; Frank Siebenhaar; Wolfgang R Sperr; Joanna N G Oude Elberink; Joseph H Butterfield; Ivan Alvarez-Twose; Karl Sotlar; Andreas Reiter; Hanneke C Kluin-Nelemans; Olivier Hermine; Jason Gotlib; Sigurd Broesby-Olsen; Alberto Orfao; Hans-Peter Horny; Massimo Triggiani; Michel Arock; Lawrence B Schwartz; Dean D Metcalfe
Journal:  J Allergy Clin Immunol Pract       Date:  2019-02-05

Review 6.  Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.

Authors:  P Valent; K Sotlar; K Blatt; K Hartmann; A Reiter; I Sadovnik; W R Sperr; P Bettelheim; C Akin; K Bauer; T I George; E Hadzijusufovic; D Wolf; J Gotlib; F-X Mahon; D D Metcalfe; H-P Horny; M Arock
Journal:  Leukemia       Date:  2017-01-16       Impact factor: 11.528

7.  The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers.

Authors:  H-P Horny; K Sotlar; F Stellmacher; M Krokowski; H Agis; L B Schwartz; P Valent
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

8.  Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology.

Authors:  Peter Valent
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

9.  Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.

Authors:  H-P Horny; K Sotlar; W R Sperr; P Valent
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

Review 10.  The serum tryptase test: an emerging robust biomarker in clinical hematology.

Authors:  Peter Valent; Wolfgang R Sperr; Karl Sotlar; Andreas Reiter; Cem Akin; Jason Gotlib; Hans-Peter Horny; Michel Arock
Journal:  Expert Rev Hematol       Date:  2014-08-28       Impact factor: 2.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.